Integration of a personalised mobile health (mHealth) application into the care of patients with brain tumours: proof-of-concept study (IDEAL stage 1). Issue 1 (22nd December 2022)

• Record Type: Journal Article
• Authors: Gvozdanovic, Andrew; Jozsa, Felix; Fersht, Naomi; Grover, Patrick James; Kirby, Georgina; Kitchen, Neil; Mangiapelo, Riccardo; McEvoy, Andrew; Miserocchi, Anna; Patel, Rayna; Thorne, Lewis; Williams, Norman; Kosmin, Michael; Marcus, Hani J
• Is Part Of: BMJ surgery, interventions, & health technologies. Volume 4:Issue 1(2022)
• Publication Date: 2022-12-22
• Subjects: health technology -- patient outcome assessment -- process assessment (health care) -- health care quality, access, and evaluation; Surgery -- Periodicals; Surgery -- Research -- Periodicals; Medical care -- Periodicals; Medical care -- Research -- Periodicals; 617.005
• DOI: 10.1136/bmjsit-2021-000130
• Languages: English
• ISSNs: 2631-4940

Abstract

Abstract : Objectives: Brain tumours lead to significant morbidity including a neurocognitive, physical and psychological burden of disease. The extent to which they impact the multiple domains of health is difficult to capture leading to a significant degree of unmet needs. Mobile health tools such as Vinehealth have the potential to identify and address these needs through real-world data generation and delivery of personalised educational material and therapies. We aimed to establish the feasibility of Vinehealth integration into brain tumour care, its ability to collect real-world and (electronic) patient-recorded outcome (ePRO) data, and subjective improvement in care. Design: A mixed-methodology IDEAL stage 1 study. Setting: A single tertiary care centre. Participants: Six patients consented and four downloaded and engaged with the mHealth application throughout the 12 weeks of the study. Main outcome measures: Over a 12-week period, we collected real-world and ePRO data via Vinehealth. We assessed qualitative feedback from mixed-methodology surveys and semistructured interviews at recruitment and after 2 weeks. Results: 565 data points were captured including, but not limited to: symptoms, activity, well-being and medication. EORTC QLQ-BN20 and EQ-5D-5L completion rates (54% and 46%) were impacted by technical issues; 100% completion rates were seen when ePROs were received. More brain cancer tumour-specific content was requested. All participants recommended the application and felt it improved care. Conclusions: Our findings indicate value in an application to holistically support patients living with brain cancer tumours and established the feasibility and safety of further studies to more rigorously assess this.